New England Medical Center Hospitals. Inc.

University of Massachusetts

Indiana University

Biogen, Incorporated

Kovina Therapeutics, Inc.

The United States of America as Represented by the Department of Health

Tufts University

New England Medical Center

The University of Mons-Hainaut

The Brigham and Women's Hospital, Inc.

Elliot J Androphy

James G Barsoum

Nirmal K Singh

Ravindra N Singh

Natalia N Singh

Samy O Meroueh

Jason J Chen

Zhijian Lu

Kevin J Hodgetts

David E Breiding

Alyssa Nicole Calder

Gregory D Cuny

John T Schiller

Douglas R Lowy

Marcie A Glicksman

Jonathan Cherry

Anne Rietz

James D Baleja

Nishita Doshi

Alexandra Belayew

Jonathon J Cherry

The invention provides compositions, compounds, formulations, and methods for treating HPV infections including pre-malignant infections and cancer. Compounds that covalently bind to the HPV E6 protein are disclosed.

Compositions and methods for treating human papilloma virus infections

Compositions and methods are provided for treating HPV infections including pre-malignant and cancers. Compounds that specifically bind to the HPV E6 protein and inactivate the protein are disclosed.

Small molecule antiviral drug treatment for human papillomavirus infections

Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.

Combination therapies for treatment of spinal muscular atrophy

The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for 'intronic splicing silencer'), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA).

Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences

Screening methods for spinal muscular atrophy

[object Object]

Methods and compositions for treating human papillomavirus infections are described.

Compounds for treating human papillomavirus

The invention is based on the elucidation of a mechanism by which HPV promotes oncogenesis and provides a methods of diagnosing malignant tumors and methods of preventing the development of malignancies or inhibiting tumor growth. A method for diagnosing a neoplasm in a mammal is carried out by measuring the level of helicase-like transcription factor (HLTF) in tissue of the mammal. An increase in the level of HLTF in the tissue compared to the level in a normal control tissue indicates the presence of a neoplasm in the tissue.

Diagnosis and treatment of cancer

E6-BP polypeptide, nucleic acids encoding E6-BP polypeptides, and uses thereof.

E6 binding proteins

E6-BP polypeptides, nucleic acids encoding E6-BP polypeptides, and uses thereof.

Growing community of inventors

Natick, MA, United States of America

Elliot J Androphy